BEAT Stock Overview
A medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HeartBeam, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.79 |
| 52 Week High | US$3.39 |
| 52 Week Low | US$1.06 |
| Beta | -0.99 |
| 11 Month Change | 14.81% |
| 3 Month Change | 22.91% |
| 1 Year Change | 103.63% |
| 33 Year Change | -27.91% |
| 5 Year Change | n/a |
| Change since IPO | -40.51% |
Recent News & Updates
Recent updates
Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation
Sep 19
Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky
Jan 17HeartBeam gets a new chief medical officer
Oct 11HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%
Sep 28HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks
Sep 15HeartBeam GAAP EPS of $0.43 beats by $0.70
Aug 11HeartBeam: Cardiovascular Diagnostics On The Go
Dec 14Shareholder Returns
| BEAT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 21.8% | 1.5% | 2.2% |
| 1Y | 103.6% | 20.8% | 31.6% |
Return vs Industry: BEAT exceeded the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: BEAT exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| BEAT volatility | |
|---|---|
| BEAT Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BEAT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BEAT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 20 | Rob Eno | www.heartbeam.com |
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection.
HeartBeam, Inc. Fundamentals Summary
| BEAT fundamental statistics | |
|---|---|
| Market cap | US$74.40m |
| Earnings (TTM) | -US$18.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs BEAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEAT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.42m |
| Earnings | -US$18.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BEAT perform over the long term?
See historical performance and comparison